PBH

SEC Filing Summary: Prestige Brands Holdings, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Prestige Brands Holdings, Inc. (also referred to as Prestige Consumer Healthcare in the prompt metadata, though the filing lists Prestige Brands Holdings, Inc.) for the three-month period ended June 30, 2008. The company markets, sells, and distributes over-the-counter healthcare, personal care, and household cleaning brands primarily in the United States and Canada. The company operates as a holding company with no direct assets or operations, serving as the parent guarantor for its debt facilities.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by 6.5% ($5.1 million) compared to the prior year. This decline was driven by decreases across all three segments: Over-the-Counter Healthcare (-7.5%), Household Cleaning (-2.9%), and Personal Care (-16.4%).
• Margin Expansion: Despite lower sales, the gross profit margin improved from 52.5% to 53.4%. This was attributed to favorable product mix, price increases on select items, and cost reduction programs, partially offset by higher promotional allowances.
• Segment Performance:
  • OTC Healthcare: Revenue declines in wart care brands (Compound W, Wartner) and Little Remedies (due to voluntary product withdrawal) offset gains in Murine, Clear Eyes, and Chloraseptic.
  • Household Cleaning: Comet brand growth was offset by declines in Spic and Span and Chore Boy.
  • Personal Care: All major brands (Cutex, Prell, Denorex) experienced revenue declines.
• Debt Reduction: The company repaid $14.1 million of its Tranche B Term Loan Facility in excess of required amortization, reducing total indebtedness from $411.2 million to $396.2 million.
• Cash Flow Improvement: Operating cash flow increased significantly by $7.0 million to $15.4 million, primarily due to a $5.9 million decrease in accounts receivable.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management intends to replace expiring credit facilities (Revolving Credit Facility maturing April 2009; Tranche B Term Loan maturing April 2011) during the period ending March 31, 2009. No specific financial guidance for future periods was provided in this text.
• Liquidity: The company has $60.0 million available under its Revolving Credit Facility. Management believes cash flows and available borrowings are sufficient to meet obligations through June 30, 2009.
• Legal Proceedings:
  • Securities Class Action: A consolidated class action lawsuit regarding the 2005 IPO remains pending. No settlement was reached in January 2008 mediation. The company intends to vigorously defend the remaining claims but cannot estimate potential loss.
  • DenTek Litigation: The company is suing DenTek Oral Care, Inc. and others for intellectual property infringement and unfair competition regarding dental protector products. A motion for preliminary injunction is pending.
• Risk Factors:
  • Customer Concentration: Approximately 27.1% of sales were made to one customer, and 59.4% of sales were derived from four major brands.
  • Supply Chain: The company relies on over 40 third-party manufacturers. The top 10 manufacturers accounted for 80% of gross sales, and the company lacks long-term contracts with some key suppliers.
  • Intangible Assets: Goodwill and intangible assets comprise the majority of the company's assets ($953 million). Future impairment charges could occur if sales or margins decline due to competition or reduced advertising support.
  • Inflation: Rising crude oil prices have adversely impacted transportation and raw material costs.

Key Facts for Investor Verification

• Debt Covenant Compliance: Verify the company's continued compliance with leverage, interest coverage, and fixed charge coverage ratios under the Senior Credit Facility and Senior Subordinated Notes.
• Refinancing Risk: Monitor the company's ability to refinance the $60 million Revolving Credit Facility and $270 million Term Loan maturing in 2009 and 2011, respectively, especially given the expiration of the accordion feature for additional borrowing.
• Product Withdrawal Impact: Assess the long-term revenue impact of the voluntary withdrawal of Little Remedies pediatric cough and cold products initiated in late 2007.
• Legal Exposure: Track developments in the securities class action lawsuit and the DenTek intellectual property litigation, as outcomes could result in significant, unquantified losses.
• Customer Concentration: Evaluate the risk associated with 27.1% of sales being dependent on a single customer and the potential impact of losing this relationship.